Konference: 2010 35th Congress ESMO – účast ČR
Kategorie: Zhoubné nádory prsu
Téma: Breast Cancer, Early
Číslo abstraktu: 0242P
The median f-up of the whole population is 41 months. During this period, 7 malignancies have been found in BRCA1/2 and CHEK2 healthy mutation carriers. One BC has been detected during the initial visit. Median time to the detection of malignancy was 28 months. One BC has been diagnosed in stage 0, 5 in stage I and 1 in stage IIB. The first abnormal findings were CA 19-9 elevation in 3 patients, breast MRI in 2 patients, mammography in 1 and breast ultrasound in 1 patient. Six of these BC have been detected during regular f-up visits. One BC occurred as an interval carcinoma.
Nine secondary malignancies have been identified among 135 HBC patients carrying mutation in BRCA1/2 gene (6 BC, 1 ovarian carcinoma, 1 pancreatic cancer and 1 lung carcinoma).
23 risk reducing salpingo-oophorectomies and/or hysterectomies have been performed among 90 healthy BRCA1/2 mutation carriers (26%). In the same cohort, prophylactic mastectomy has been carried out in 4 of 90 women (4.5%). The low proportion of prophylactic surgical procedures is caused by low mean and median ages of these women.
Table 1. Basic characteristic of tested population.
|Analyzed gene||No. tested individuals||No. tested families||No. mut. carriers|
Conclusion: Specific preventive program for mutation carriers is an effective option for identification of high/risk BC patients at early and highly curable stages. Acknowledgement: The study was supported by the grant MSM0021620808.
Disclosure: All authors have declared no conflicts of interest.
Datum přednesení příspěvku: 10. 9. 2010